| Autor: |
ZHANG Xuanling, CHEN Chaoyang, WEI Ran, ZHOU Ying |
| Jazyk: |
čínština |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
罕见病研究, Vol 3, Iss 2, Pp 246-251 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2097-0501 |
| DOI: |
10.12376/j.issn.2097-0501.2024.02.015 |
| Popis: |
Neuromyelitis optic spectrum disorders (NMOSD) is a serious inflammatory demyelinating disease. Clinical treatment of NMOSD mainly involves acute phase treatment and remission phase prevention treatment. Disease-modifying therapy (DMT) in remission phase of NMOSD can effectively reduce disease recurrence and delay disability progression. At present, the drugs commonly used for DMT at home and abroad include classical immunosuppression, B-cell surface antigen monoclonal antibody, complement targeting monoclonal antibody, IL-6 receptor-targeting monoclonal antibody, etc. This paper mainly reviews the DMT drugs efficacy, safety, as well as the marketing status of NMOSD. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
